{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:26:35Z","timestamp":1778797595722,"version":"3.51.4"},"reference-count":38,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003524","name":"Ministry of Business, Innovation and Employment","doi-asserted-by":"publisher","award":["RTVU1503"],"award-info":[{"award-number":["RTVU1503"]}],"id":[{"id":"10.13039\/501100003524","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Great New Zealand Trek Charitable Trust"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2020,6,1]]},"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Because clozapine and risperidone have been shown to reduce neuroinflammation in humans and mice, the Clozapine and Risperidone in Progressive Multiple Sclerosis (CRISP) trial was conducted to determine whether clozapine and risperidone are suitable for progressive multiple sclerosis (pMS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The CRISP trial (ACTRN12616000178448) was a blinded, randomised, placebo-controlled trial with three parallel arms (n=12\/arm). Participants with pMS were randomised to clozapine (100\u2013150\u2009mg\/day), risperidone (2.0\u20133.5\u2009mg\/day) or placebo for 6\u2009months. The primary outcome measures were safety (adverse events (AEs)\/serious adverse events (SAE)) and acceptability (Treatment Satisfaction Questionnaire for Medication-9).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>An interim analysis (n=9) revealed significant differences in the time-on-trial between treatment groups and placebo (p=0.030\u2009and 0.025, clozapine and risperidone, respectively) with all participants receiving clozapine being withdrawn during the titration period (mean dose=35\u00b115\u2009mg\/day). Participants receiving clozapine or risperidone reported a significantly higher rate of AEs than placebo (p=0.00001) but not SAEs. Specifically, low doses of clozapine appeared to cause an acute and dose-related intoxicant effect in patients with pMS who had fairly severe chronic spastic ataxic gait and worsening over all mobility, which resolved on drug cessation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>The CRISP trial results suggest that patients with pMS may experience increased sensitivity to clozapine and risperidone and indicate that the dose and\/or titration schedule developed for schizophrenia may not be suitable for pMS. While these findings do not negate the potential of these drugs to reduce multiple sclerosis-associated neuroinflammation, they highlight the need for further research to understand the pharmacodynamic profile and effect of clozapine and risperidone in patients with pMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ACTRN12616000178448.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2020-000060","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T01:55:12Z","timestamp":1594346112000},"page":"e000060","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase I, randomised, blinded, placebo-controlled trial"],"prefix":"10.1136","volume":"2","author":[{"given":"Anne C","family":"La Flamme","sequence":"first","affiliation":[{"name":"School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand"},{"name":"Malaghan Institute of Medical Research, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Abernethy","sequence":"additional","affiliation":[{"name":"Neurology, Wellington Regional Hospital, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalice","family":"Sim","sequence":"additional","affiliation":[{"name":"Biostatistical Consulting Group, University of Otago, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liz","family":"Goode","sequence":"additional","affiliation":[{"name":"Neurology, Wellington Regional Hospital, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Lockhart","sequence":"additional","affiliation":[{"name":"Pharmaceuticol Ltd, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Bourke","sequence":"additional","affiliation":[{"name":"Neurology, Wellington Regional Hospital, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imogen","family":"Milner","sequence":"additional","affiliation":[{"name":"Neurology, Wellington Regional Hospital, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni-Marie","family":"Garrill","sequence":"additional","affiliation":[{"name":"Neurology, Wellington Regional Hospital, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purwa","family":"Joshi","sequence":"additional","affiliation":[{"name":"Neurology, Wellington Regional Hospital, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eloise","family":"Watson","sequence":"additional","affiliation":[{"name":"Neurology, Wellington Regional Hospital, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duncan","family":"Smyth","sequence":"additional","affiliation":[{"name":"Neurology, Wellington Regional Hospital, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Lance","sequence":"additional","affiliation":[{"name":"Hutt Valley District Health Board, Lower Hutt, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bronwen","family":"Connor","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"2025072812230742000_2.1.e000060.1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.52.1.503"},{"key":"2025072812230742000_2.1.e000060.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1566-2772(03)00021-5"},{"key":"2025072812230742000_2.1.e000060.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.05.006"},{"key":"2025072812230742000_2.1.e000060.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.01.019"},{"key":"2025072812230742000_2.1.e000060.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2004.05.047"},{"key":"2025072812230742000_2.1.e000060.6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001084"},{"key":"2025072812230742000_2.1.e000060.7","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbt141"},{"key":"2025072812230742000_2.1.e000060.8","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2013.11.3.144"},{"key":"2025072812230742000_2.1.e000060.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(00)00094-3"},{"key":"2025072812230742000_2.1.e000060.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(01)00221-4"},{"key":"2025072812230742000_2.1.e000060.11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104430","article-title":"Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis","volume":"9","author":"O'Sullivan","year":"2014","journal-title":"PLoS One"},{"key":"2025072812230742000_2.1.e000060.12","first-page":"205521731769872","article-title":"Enhanced disease reduction using clozapine, an atypical antipsychotic agent, and glatiramer acetate combination therapy in experimental autoimmune encephalomyelitis","volume":"3","author":"Green","year":"2017","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"2025072812230742000_2.1.e000060.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216113","article-title":"Clozapine administration enhanced functional recovery after cuprizone demyelination","volume":"14","author":"Templeton","year":"2019","journal-title":"PLoS One"},{"key":"2025072812230742000_2.1.e000060.14","doi-asserted-by":"crossref","first-page":"029","DOI":"10.1055\/s-2007-1019124","article-title":"The immunology of multiple sclerosis","volume":"28","author":"Bar-Or","year":"2008","journal-title":"Semin Neurol"},{"key":"2025072812230742000_2.1.e000060.15","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.168"},{"key":"2025072812230742000_2.1.e000060.16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00415-008-1002-8","article-title":"A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis","volume":"255(Suppl 1)","author":"Weiner","year":"2008","journal-title":"J Neurol"},{"key":"2025072812230742000_2.1.e000060.17","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107083997"},{"key":"2025072812230742000_2.1.e000060.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2004.05.010"},{"key":"2025072812230742000_2.1.e000060.19","unstructured":"Adult clozapine titration chart, 2012. Available: http:\/\/www.safetyandquality.gov.au\/wp-content\/uploads\/2013\/01\/National-Adult-Clozapine-Titration-Chart.pdf"},{"key":"2025072812230742000_2.1.e000060.20","unstructured":"Medsafe . Clozapine \u00ad close monitoring required. prescriber update ed, 2015: 18\u201321."},{"key":"2025072812230742000_2.1.e000060.21","unstructured":"Medsafe . New Zealand data sheet: Clozaril\u00ae (clozapine), 2011."},{"key":"2025072812230742000_2.1.e000060.22","unstructured":"Freudenreich O , McEvoy J . Marder S , ed. Guidelines for prescribing clozapine in schizophrenia [Internet], 2020. http:\/\/www.uptodate.com\/contents\/guidelines-for-prescribing-clozapine-in-schizophrenia"},{"key":"2025072812230742000_2.1.e000060.23","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-36"},{"key":"2025072812230742000_2.1.e000060.24","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.1.64"},{"key":"2025072812230742000_2.1.e000060.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2011.01710.x"},{"key":"2025072812230742000_2.1.e000060.26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0278-5846(03)00164-7","article-title":"Risperidone in acute and long-term therapy of schizophrenia--a clinical profile","volume":"28","author":"Pajonk","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2025072812230742000_2.1.e000060.27","unstructured":"Medsafe . DP-risperidone, 2005."},{"key":"2025072812230742000_2.1.e000060.28","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0411"},{"key":"2025072812230742000_2.1.e000060.29","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033333"},{"key":"2025072812230742000_2.1.e000060.30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/10401239609147758","article-title":"Subjective muscle weakness and hypotonia during clozapine treatment","volume":"8","author":"Galletly","year":"1996","journal-title":"Ann Clin Psychiatry"},{"key":"2025072812230742000_2.1.e000060.31","first-page":"107","article-title":"Motor and mental side effects of clozapine","volume":"55(Suppl B)","author":"Gerlach","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"2025072812230742000_2.1.e000060.32","first-page":"603","article-title":"The pharmacology of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine (clozapine)","volume":"26","author":"Stille","year":"1971","journal-title":"Farmaco Prat"},{"key":"2025072812230742000_2.1.e000060.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(97)71418-X"},{"key":"2025072812230742000_2.1.e000060.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2011.11.014"},{"key":"2025072812230742000_2.1.e000060.35","first-page":"414","article-title":"Rash and desquamation associated with risperidone oral solution","volume":"10","author":"Chae","year":"2008","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"2025072812230742000_2.1.e000060.36","doi-asserted-by":"publisher","DOI":"10.1586\/ern.10.85"},{"key":"2025072812230742000_2.1.e000060.37","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2015.00257","article-title":"Remyelination therapy in multiple sclerosis","volume":"6","author":"Harlow","year":"2015","journal-title":"Front Neurol"},{"key":"2025072812230742000_2.1.e000060.38","unstructured":"Metz L . Safety and tolerability of quetiapine in multiple sclerosis. Bethesda, MD: National Library of Medicine (US), 2000. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02087631"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2020-000060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T19:23:13Z","timestamp":1753730593000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2020-000060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,7,9]]},"published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1136\/bmjno-2020-000060"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2020-000060","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.03.12.20034983","asserted-by":"object"}]},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}